Multiple Myeloma
Copyright policy )Multiple Myeloma
AbstractMultiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present a historically focused review of the disease, from the description of the first case in 1844 to the present. The evolution of drug therapy and stem-cell transplantation for the treatment of myeloma, as well as the development of new agents, is discussed. We also provide an update on current concepts of diagnosis and therapy, with an emphasis on how treatments have emerged from a historical perspective after certain important discoveries and the results of experimental studies.
- Mayo Clinic United States
Remission Induction, Paraproteinemias, Antineoplastic Agents, History, 19th Century, History, 20th Century, Boronic Acids, Combined Modality Therapy, History, 21st Century, Thalidomide, Bortezomib, Risk Factors, Pyrazines, Disease Progression, Biomarkers, Tumor, Animals, Humans, Protease Inhibitors, Multiple Myeloma, Lenalidomide, Randomized Controlled Trials as Topic, Stem Cell Transplantation
Remission Induction, Paraproteinemias, Antineoplastic Agents, History, 19th Century, History, 20th Century, Boronic Acids, Combined Modality Therapy, History, 21st Century, Thalidomide, Bortezomib, Risk Factors, Pyrazines, Disease Progression, Biomarkers, Tumor, Animals, Humans, Protease Inhibitors, Multiple Myeloma, Lenalidomide, Randomized Controlled Trials as Topic, Stem Cell Transplantation
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).2K popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 0.1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 0.1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 0.1%
Citations provided by BIP!Popularity provided by BIP!